Buysignal
#btcstarburst UPDATE… HMMI would guess … We would be going up towards 24k… break that 26k ish… who knows any more. GANN STUDY…
BOTTOM IS CLOSE ON BTC!!!In this video i am explaining where i think we are going to go from here and also i'm looking at the 4 hourly, daily, weekly and monthly chart, as well i am looking at inflation rate chart and DXY .
This is my third video and i hope you'll like it. Also i'm sorry for my speaking mistakes, I'm trying to improve my english.
I forgot to mention that 300 weekly ma is also at the bottom of my monthly channel and also i forgot to mention that i am still in my short position from the top of the range at 32400k.
What do you think about my second third video and analysis ?
Feel free to leave a comment.
If you like my ideas please follow me and like because you can always find something interesting on my profile, i am new to Treadingview but i have 6 years expirience in trading.
DON'T SELL YOUR CRYPTO
BTC TO THE MOON!!!
USDCHF BUY IDEAUSDCHF is rejeced from an ordere block on daily time frame
we can look for a swing buy opportunity and our target would be at the end of the FVG 0.99226
GBPJPY buyGBPJPY touched the bullish trend line signals entry buy
GBPJPY touched the bullish trend line signals entry buy
GBPJPY touched the bullish trend line signals entry buy
$SIDU Next Target PT 11 and higher Long term PT 60 and higherSidus Space is a Teammate on NASA’s $3.5 Billion Exploration Extravehicular Activity Services Contract
Sidus Space, Inc. (NASDAQ:SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support is proud to announce that it is part of the Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity (xEVAS) services contract.
Sidus Space, Inc., a space-as-a-service company, engages in the design, manufacture, launch, and data collection of commercial satellite worldwide. Its services include satellite manufacturing; precision manufacturing, assembly, and test; low earth orbit microsatellite; payload integrations; launch and support services; space-based data services and analytics; precision computer numerical control machining and fabrication; Swiss screw machining; wire cable harness fabrication; 3D composite and metal printing; and satellite deployment and microgravity testing and research services, as well as services related to electrical and electronic assemblies. The company also offers hardware solutions consisting of an external flight test platform to develop, test, and fly experiments, as well as delivers hardware, materials, and advanced electronics on the international space station; and space station integrated kinetic launcher for orbital payload systems. It serves commercial space, aerospace, defense, underwater marine, and other commercial and government customers. The company was founded in 2014 and is headquartered in Merritt Island, Florida. Sidus Space, Inc. is a subsidiary of Craig Technical Consulting, Inc.
$BKSY Next Target PTs 4-4.75 Long term PT 29 and higherBlackSky Technologies Inc. (NYSE: BKSY) was awarded a basic order agreement from the Joint Artificial Intelligence Center (JAIC) to create and optimize data sets for use in DoD AI models and applications. The JAIC agreement has a ceiling value of $241 million over five years.
BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operations of satellite and ground systems to commercial and government customers worldwide. The company processes a range of observations from its constellation, as well as various space, internet-of-things, and terrestrial based sensors and data feeds. Its products are used in government defense and intelligence; commercial, construction, and industrial; and catastrophe, climate, and environment applications. The company was incorporated in 2014 and is headquartered in Herndon, Virginia.
AUDCAD: Reversal Zones 🔄Price has trapped sellers with the false breakout of the head and shoulders.
Since we have already swept a strong area of support to the left, I believe price may want to react at one of these major demands for buyers.
I have my alerts set and will take a buy trade with the team IF criteria is met.
Traders, if you have your own opinion about this idea, write in the comments section, I always reply. 💬
--------------------------------------------------------------------------------------------------------
Please like, subscribe, and share this idea with others! ⬇️
--------------------------------------------------------------------------------------------------------
NEAR strong supportNear protocol is oversold at a strong support level.
I expect a reversal to $4.80 before heading lower this year.
Looking forward to read your opinion about it.
MANAUSDTIf the price goes out of the bearish channel in this way, it can easily increase to the blue range of $ 1,2294 !!!
Of course, the risk of decreasing from the bottom to the yellow range ($ 0.55578) should be considered !!!
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well.
Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year.
Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
KDAUSDTin my opinion this coin is on support zone
entries is clear but the stop for the second position will be updated after the price break the trend line
TWTUSDTTrue, the whole market is negative, but it has managed to maintain its upward channel
Most importantly, we did not miss the limits!
It seems to be able to show a positive reaction on the price range of $ 0.5193 and have an upward trend up to the specified range.
GBPUSD buy opportunitywe have 2 way to buy gbpusd after it down to support level or after breakout 1.2340
our buy target
1- 2420
2- 2520
Btc trade take booked profiti have taken a trade today based on indicator and a bit of chart analysis
CADCHF Long Trade OpportunityA 'buy' opportunity has just presented itself on the loonie-swissy trading chart. This is occasioned by the bullish harami candlestick pattern which closes just above the 0.74593 horizontal support level, which signals a fakeout and suggests an upward price movement.
You can still enter this trade by setting your stop slightly below the level mentioned earlier and placing your target anywhere between your entry price and the 0.78000 psychological level (ensuring a reward-to-risk ratio of at least 3.00).
Happy trading!
Buy and Sell possibilities for Chainlink Simple chart to guide buy and sell opportunities. This is just a projection. Do your own research.
OIL 1hr Buy SignalStochastic RSI 20% bullish crossing is a dependable buy signal (or sell signal).
The stop should go below the current recent higher low. Remember to use 1% risk
maximum so calculate your position size correctly.
Can we Fill the Clean Range? (GBPUSD)Hi Traders,
GBPUSD has broken a 4-hour resistance level, The current h4 candle has wicked down to come all the way up and break structure, That is a sign of a lot of money being poured into the buys, I do expect the continuation and I would love to see price retest the broken resistance and then go for the highs of 1.2825.
We will, as always, need to see the price close above before even considering the buys, To back up my analysis we also have an inverse head and shoulders.
Happy Trading.
Renaldo Philander
$AERC entry PTs 16-17.70 Next Target PT 28 and higher Long term AeroClean Technologies, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. It provides Purgo, an air sanitization product for indoor spaces; and Purgo Lift that provides air purification solution for elevators and other wall-mount applications. The company was formerly known as AeroClean Technologies, LLC. AeroClean Technologies, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
